Skip to Main Content
Phase III

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

  • Study IRB#:2000040789
  • Last Updated:11/17/2026

This study is evaluating the maintenance effect of an investigational drug as an adjunctive therapy for Major Depressive Disorder. The investigational drug is called osavampator and it is intended to work the same way that ketamine does. All patients receive open-label drug meaning not a placebo for 16 weeks. Those who respond are randomized to continue the drug or receive placebo until relapse; those who relapse on placebo can get the drug again in extended open-label and can get ongoing maintenance for 1+ year(s).

  • Age18 years and older
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877-978-8343 for more information.

Study Location

  • Yale University

Eligibility Criteria

Inclusion Criteria:

1. 18 years or older

2. BMI of 18 to 42 kg/m2

3. Primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder

4. Must be receiving 1 or more oral antidepressant(s) that they have been taking for 4 weeks or longer prior to screening AND be willing to continue same treatment at same dose/frequency throughout the study. Past medication trials must be able to be confirmed (prescription, pharmacy records, health insurance data).

5. Must have an inadequate response (less than 50% improvement) to 1 to 5 oral antidepressant trials(including current antidepressant) in current depressive episode

6. Total HAMD-17 score of 22 or higher at screening and baseline

7. If receiving psychotherapy, can continue; however, CBT must have been ongoing for the last 3 months prior to baseline. New psychotherapy may not be initiated during this study

8. Normal thyroid function; if on thyroid medication, must be on stable dose x 3 months

9. Negative pregnancy test at screening and baseline (females of childbearing potential)

10. Females of childbearing potential must agree to use acceptable contraception from screening to final study visit

Exclusion Criteria:

1. Current or prior primary psychiatric diagnosis (in last 1 year) other than MDD

2. Co-morbid personality disorder that may interfere with study participation

3. Diagnosis of neurodegenerative disorders, eating disorder, schizophrenia, schizoaffective disorder, bipolar disorder, MDD with psychotic features or mixed features, intellectual disability or mental disorders due to a medical condition

4. Considered to be at imminent risk of suicide or injury to self/others (suicide attempt in previous year, suicidal ideation with intent and / or plan in last 6 months)

5. Moderate to severe substance or alcohol use disorder (except: caffeine, nicotine) in the last 1 year; cannabis permissible if use is limited to < or = 3x/week

6. Positive urine tox at screening or baseline (alcohol, barbiturates, phencyclidine, cocaine, opiates, amphetamines, methadone, unprescribed benzodiazepines)

7. Taking a daily dose of prescription benzodiazepines greater than equivalent of 4mg/day of lorazepam

8. Currently taking long-acting anti-psychotic medications

9. Current or recent enrollment in other investigational studies (excluding vaccine trials)

10. Pregnant, lactating or planning to become pregnant during the study

11. Unstable medical condition currently or in past 3 months or cancer within past 6 months

12. History of epilepsy, seizures or convulsions (except infantile febrile seizures) or 1st degree relative with seizure disorder

13. History of neurological abnormalities including brain injury (including traumatic injury), perinatal cerebropathy, and postnatal brain damage, blood-brain barrier abnormality, and cavernous angioma.

14. Diagnosis of AIDS, prolonged QTcF (>450 msec), elevated creatinine (>1.2xULN), elevated LFT’s (>3x ULN), anemia (Hgb <10g/dL), WBC < 3, platelet count < 1000/mm3, ANC <1, HbA1c >7.5%

Principal Investigator

Sub-Investigator

For more information about this study, including how to volunteer, contact: